Trulicity

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
16-03-2023
Produktens egenskaper Produktens egenskaper (SPC)
16-03-2023

Aktiva substanser:

dulaglutide

Tillgänglig från:

Eli Lilly Nederland B.V.

ATC-kod:

A10BJ05

INN (International namn):

dulaglutide

Terapeutisk grupp:

Drugs used in diabetes, Blood glucose lowering drugs, excl. insulins

Terapiområde:

Diabetes Mellitus, Type 2

Terapeutiska indikationer:

Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Produktsammanfattning:

Revision: 17

Bemyndigande status:

Authorised

Tillstånd datum:

2014-11-21

Bipacksedel

                                72
B. PACKAGE LEAFLET
73
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TRULICITY 0.75 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 1.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 3 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 4.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
dulaglutide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trulicity is and what it is used for
2.
What you need to know before you use Trulicity
3.
How to use Trulicity
4.
Possible side effects
5.
How to store Trulicity
6.
Contents of the pack and other information
1.
WHAT TRULICITY IS AND WHAT IT IS USED FOR
Trulicity contains an active substance called dulaglutide and is used
to lower blood sugar (glucose) in
adults and children aged 10 years and above, with type 2 diabetes
mellitus and can help prevent heart
disease.
Type 2 diabetes is a condition in which your body does not make enough
insulin, and the insulin that
your body produces does not work as well as it should.
When this happens, sugar (glucose) builds up in the blood.
Trulicity is used:
-
on its own if your blood sugar is not properly controlled by diet and
exercise alone, and you
can’t take metformin (another diabetes medicine).
-
or with other medicines for diabetes when they are not enough to
control your blood sugar
levels. These other medicines may be medicines taken by mouth and/or
insulin given by
injection.
It is important to continue to follow the advice on diet and exercise
given to you by your doctor,
pharmac
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trulicity 0.75 mg solution for injection in pre-filled pen
Trulicity 1.5 mg solution for injection in pre-filled pen
Trulicity 3 mg solution for injection in pre-filled pen
Trulicity 4.5 mg solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trulicity 0.75 mg solution for injection in pre-filled pen
Each pre-filled pen contains 0.75 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 1.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 1.5 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 3 mg solution for injection in pre-filled pen
Each pre-filled pen contains 3 mg of dulaglutide* in 0.5 ml solution.
Trulicity 4.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 4.5 mg of dulaglutide* in 0.5 ml
solution.
*produced in CHO cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Type 2 Diabetes Mellitus
Trulicity is indicated for the treatment of patients 10 years and
above with insufficiently controlled
type 2 diabetes mellitus as an adjunct to diet and exercise
•
as monotherapy when metformin is considered inappropriate due to
intolerance or
contraindications
•
in addition to other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic
control and cardiovascular events,
and the populations studied, see sections 4.4, 4.5 and 5.1.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
_Adults _
_ _
_Monotherapy _
The recommended dose is 0.75 mg once weekly.
_Add-on therapy_
The recommended dose is 1.5 mg once weekly.
If needed,
•
the 1.5 mg dose can be increased after at least 4 weeks to 3 mg once
weekly.
•
the 3 mg dose can be increased after at least 4 weeks to 4.5 mg once
weekly.
The maximum dose is 4.5 mg once weekly.
_Paediatri
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 16-03-2023
Produktens egenskaper Produktens egenskaper bulgariska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 16-03-2023
Bipacksedel Bipacksedel spanska 16-03-2023
Produktens egenskaper Produktens egenskaper spanska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 16-03-2023
Bipacksedel Bipacksedel tjeckiska 16-03-2023
Produktens egenskaper Produktens egenskaper tjeckiska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 16-03-2023
Bipacksedel Bipacksedel danska 16-03-2023
Produktens egenskaper Produktens egenskaper danska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 16-03-2023
Bipacksedel Bipacksedel tyska 16-03-2023
Produktens egenskaper Produktens egenskaper tyska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 16-03-2023
Bipacksedel Bipacksedel estniska 16-03-2023
Produktens egenskaper Produktens egenskaper estniska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 16-03-2023
Bipacksedel Bipacksedel grekiska 16-03-2023
Produktens egenskaper Produktens egenskaper grekiska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 16-03-2023
Bipacksedel Bipacksedel franska 16-03-2023
Produktens egenskaper Produktens egenskaper franska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 16-03-2023
Bipacksedel Bipacksedel italienska 16-03-2023
Produktens egenskaper Produktens egenskaper italienska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 16-03-2023
Bipacksedel Bipacksedel lettiska 16-03-2023
Produktens egenskaper Produktens egenskaper lettiska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 16-03-2023
Bipacksedel Bipacksedel litauiska 16-03-2023
Produktens egenskaper Produktens egenskaper litauiska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 16-03-2023
Bipacksedel Bipacksedel ungerska 16-03-2023
Produktens egenskaper Produktens egenskaper ungerska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 16-03-2023
Bipacksedel Bipacksedel maltesiska 16-03-2023
Produktens egenskaper Produktens egenskaper maltesiska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 16-03-2023
Bipacksedel Bipacksedel nederländska 16-03-2023
Produktens egenskaper Produktens egenskaper nederländska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 16-03-2023
Bipacksedel Bipacksedel polska 16-03-2023
Produktens egenskaper Produktens egenskaper polska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 16-03-2023
Bipacksedel Bipacksedel portugisiska 16-03-2023
Produktens egenskaper Produktens egenskaper portugisiska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 16-03-2023
Bipacksedel Bipacksedel rumänska 16-03-2023
Produktens egenskaper Produktens egenskaper rumänska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 16-03-2023
Bipacksedel Bipacksedel slovakiska 16-03-2023
Produktens egenskaper Produktens egenskaper slovakiska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 16-03-2023
Bipacksedel Bipacksedel slovenska 16-03-2023
Produktens egenskaper Produktens egenskaper slovenska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 16-03-2023
Bipacksedel Bipacksedel finska 16-03-2023
Produktens egenskaper Produktens egenskaper finska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 16-03-2023
Bipacksedel Bipacksedel svenska 16-03-2023
Produktens egenskaper Produktens egenskaper svenska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 16-03-2023
Bipacksedel Bipacksedel norska 16-03-2023
Produktens egenskaper Produktens egenskaper norska 16-03-2023
Bipacksedel Bipacksedel isländska 16-03-2023
Produktens egenskaper Produktens egenskaper isländska 16-03-2023
Bipacksedel Bipacksedel kroatiska 16-03-2023
Produktens egenskaper Produktens egenskaper kroatiska 16-03-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 16-03-2023

Sök varningar relaterade till denna produkt

Visa dokumenthistorik